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Background. Decentralization of antiretroviral therapy (ART) services is a key strategy to achieving universal access to treatment
for people living with HIV/AIDS. Our objective was to assess clinical and laboratory outcomes within a decentralized program
in Nigeria. Methods. Using a tiered hub-and-spoke model to decentralize services, a tertiary hospital scaled down services to 13
secondary-level hospitals using national and program guidelines. We obtained sociodemographic, clinical, and immunovirologic
data on previously antiretroviral drug na¨ ıve patients aged ≥15 years that received HAART for at least 6 months and compared
treatment outcomes between the prime and satellite sites. Results. Out of 7,747 patients, 3729 (48.1%) were enrolled at the satellites
while on HAART, prime site patients achieved better immune reconstitution based on CD4+ cell counts at 12 (𝑃 < 0.001)a n d2 4
weeks(𝑃 < 0.001)withsimilarresponsesat48weeks(𝑃 = 0.11) andhigher rates ofviralsuppression(<400c/mL)at12(𝑃 < 0.001)
and 48 weeks (𝑃 = 0.03), but similar responses at 24 weeks (𝑃 = 0.21). Mortality was 2.3% versus 5.0% (𝑃 < 0.001)a tp r i m ea n d
satellite sites, while transfer rate was 8.7% versus 5.5% (𝑃 = 0.001)a tp r i m ea n ds a t e l l i t e s .Conclusion. ART decentralization is
feasible in resource-limited settings, but efforts have to be intensified to maintain good quality of care.
1. Introduction
Nigeria bears the second largest burden of HIV infection
i nA f r i c a ,s e c o n do n l yt oS o u t hA f r i c a .O ft h ee s t i m a t e d1 . 4
million HIV-infected persons needing antiretroviral therapy
(ART), only one-third of them were accessing treatment
at the end of 2012 [1]. Universal access to ART remains a
challenge in most of sub-Saharan Africa (SSA). The United
Nations Millennium Development Goals (MDGs) were
enacted in the year 2000 and MDG 6 advocated for universal
access to ART by 2010. However, at the end of the decade,
only 6.6 million (47%) of the estimated 14.2 million people
eligible for treatment in low- and middle-income countries
(LMIC) were accessing ART. Large-scale, vertical treatment
programsinurbanareashavelargelybeenresponsibleforthe
rapid expansion of ART services in Africa, with many rural
communities still lacking access to HIV and AIDS services
[2–4].
Published reports indicate that ART can be delivered
effectively in Africa, with individual biological and immuno-
logicalresponsestoARTequivalenttothoseinhigh-resource
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settings [5–9]. National programs [10–13]h a v er e p o r t e d
large-scale data of HIV treatment in both urban and rural
populations [14–17]; however, delivery of HIV treatment in
some settings presents unique challenges and current ART
delivery models may significantly limit the accessibility of
ART. To have the greatest impact on public health, HIV
treatment programs will have to be decentralized and inte-
grated into the existing health care system. Decentralization
thereforeisakeystrategytowardsachievingtheMDGgoalof
universal access to ART services. Preliminary evidence from
suchruralprogramshasdemonstratedthatARTprovisionin
ruralcommunitiesisfeasible,giventheappropriateresources
and infrastructure.
Concern has been raised that the rapid expansion of
H I Vs e r v i c e sw i l lr e d u c et h eq u a l i t yo fc a r ef o ri n d i v i d u a l s
within the programs as capacity and resources are stretched
[16]. Characteristics of individuals accessing treatment may
change over time, and this may affect overall outcomes;
therefore monitoring treatment outcomes is essential to
identify constraints or deficiencies in program performance.
Guidelines for the decentralization of ART services were
recently released in Nigeria and as such, there is limited data
a s s e s s i n go u t c o m e sa tt h el e v e lo fp r o g r a mi m p l e m e n t a t i o n .
Our objectives were to explore baseline characteristics of
patients enrolled in a decentralized ART program and to
compareclinicalandlaboratorytreatmentoutcomesbetween
patients within the first year of highly active antiretroviral
therapy (HAART).
2. Materials and Methods
2.1. Patients. The AIDS Prevention Initiative in Nigeria
(APIN) and Harvard School of Public Health HIV program,
supported by a grant from the United States President’s
Emergency Plan for AIDS Relief (PEPFAR), has supported
the provision of treatment and care services to HIV-infected
patients at the Jos University Teaching Hospital (JUTH),
North Central Nigeria, since 2004. All patients enrolled in
the JUTH PEPFAR supported program provided written
consent for care; data for those that also consented for use
of their information in future analyses were evaluated. The
treatmentprotocolandwrittenconsentwereapprovedbythe
institutional review boards (IRBs) at JUTH and the Harvard
School of Public Health. Approval for secondary use of
treatment data for this study was also obtained from the IRB
at the Harvard School of Public Health.
This retrospective cohort analysis was performed using
routine treatment data from patients enrolled at a tertiary
hospital: Jos University Teaching Hospital (JUTH), (prime
site or “hub”) and 13 secondary-level health centers (satellite
sites or “spoke”) between June 2007 and May 2011. ART eligi-
bility was based on the Nigerian National Adult ART Guide-
lines [16], with ART recommended for all individuals with
CD4 counts <200cells/mm
3 and for those individuals with
WHO clinical stage 3 or 4 and CD4 counts <350cells/mm
3.
Recommended first-line ART included a nonnucleoside
reverse transcriptase inhibitor (NNRTI) plus 2 nucleoside
reverse transcriptase inhibitors. Once patients were assessed
for eligibility, they were asked to return for both group and
individualcounselingandeducationsessionstopreparethem
for ART. During the first year of HAART, all patients had
baseline evaluation. This was repeated at 3 and 6 months.
Those with detectable viral loads at 6 months had their next
evaluation at 9 months. However, those with undetectable
viral loads at 6 months had their next evaluation at 12
months, provided that there were no adverse events to
warrant more frequent monitoring. Laboratory monitoring
for follow-up included hematological indices, biochemical
parametersincludingliverenzymes,serumcreatinine,fasting
b l o o ds u g a r ,a n dt o t a lc h o l e s t e r o l ,a n dC D 4c o u n ta n dv i r a l
load monitoring.
The study cohort consisted of ART-naive patients ≥15
y e a r so fa g ef o rw h o ma tl e a s t6m o n t h so ft r e a t m e n tf o l l o w -
up were available.
2.2. Laboratory Analysis. CD4 count measurement was per-
formedusinglaser-basedflow-cytometricenumerationtech-
n i q u e( C y fl o w ,P a r t e cG m b H ,M u n s t e r ,G e r m a n y ) .P l a s m a
HIV-1 RNA polymerase chain reaction determination was
performed using the Roche Amplicor Monitor assay, version
1.5(RocheDiagnostics,NJ,USA).Alllaboratoriesparticipate
in regular external quality-control programs for HIV infec-
tiondiagnosis,CD4+cellcountenumeration,andplasmaVL
estimation. At the prime site, HBsAg was determined using
enzyme immunoassay (EIA) (Monolisa HBsAg Ultra3; Bio-
Rad) and HCV antibody was tested using third generation
EI A(DI A.PRODiagnostic,Bioprobessrl,Milan,I taly).A tthe
satellites,hepatitisstatuswasdeterminedusingrapidtest kits
(Abon Biopharm Co., Ltd., Hangzhou, China).
2.3.DataCollection. Patientdatawerecollectedonstandard-
ized clinic forms and entered into a customized electronic
record database (FileMaker Pro) by trained data staff at each
site. Baseline evaluations included medical history, physical
examination, WHO clinical staging, complete blood counts,
C D 4c o u n t ,a n dp l a s m aV L .Th e s es a m ec l i n i c a la n dl a b o r a -
tory evaluations were performed 3 and 6 months after ART
initiation and then approximately every 6 months thereafter
unless symptoms required more frequent monitoring.
2.4. Description of Decentralization Model. From June 2007,
the Harvard PEPFAR/APIN Plus program at JUTH com-
menced statewide provision of ART services in Plateau State.
This was accomplished using the “hub-and-spoke” model
(Figure 1). The hub (prime site) was the urban-located JUTH
fromwhereservicesweredecentralizedtothe13satellitesites
within Plateau State. The satellite sites were secondary-level
hospitals located at semiurban and rural communities within
different local government areas in the state. The satellite
clinics were a mix of government, faith-based, and for-profit
centres. They all were secondary-level facilities and offered
general medical services including surgical, obstetrics, and
pediatric care. They had different resource bases, but for the
implementation of comprehensive HIV/AIDS services, their
systems received the same level of support and equipment.AIDS Research and Treatment 3
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Figure 1: Hub-and-spoke model of ART decentralization in Jos,
Nigeria (PHC: primary health centre; ↔ two-way flow of referrals;
and → one-way flow of referrals).
None of the satellite sites had experience with imple-
mentation of comprehensive ART services. However, all of
them were providing HCT and single-dose nevirapine based
PMTCT services prior to the scale-out process. Each of the
secondary-level facility was in turn linked to at least three
primary health centers (PHCs).
Th efi r s ts t e pb e g a ni n2 0 0 6w i t hs i t ea s s e s s m e n ta n d
selection. Sites were chosen based on the following cri-
teria: (i) availability of medical doctors/nurses/laboratory
scientists/pharmacists and other support staff; most cadres
of health care personnel were present at the satellite sites;
however, they were present in limited numbers compared
t ot h et e r t i a r ys i t ew h e r et h ea b s o l u t en u m b e r so fs t a ffw e r e
higher; (ii) available HIV testing and counseling (HTC)
services; (iii) the presence of adequate counseling and con-
sulting rooms; (iv) capability for safe and secure storage of
drugs; and (v) number of patients in need of treatment.
Facilities that had adequate patient load but failed to meet the
minimumcriteriareceived healthsystems strengtheningand
logistical support to operate comprehensive HIV services.
The next step involved capacity building and training of
health workers using standardized national training tools. In
addition to centrally organized trainings, each satellite site
received weekly mentorship visits from the satellite team.
The team comprised of specialist physicians, an obstetrician,
nurse counselors, data personnel, laboratory scientist, and
p h a r m a c i s t .Th et e a mv i s i t e dt h es i t e so nt h e i rc l i n i cd a y s
and provided hands-on training. The third step involved the
roll-out and implementation of comprehensive ART services
through integration of ART follow-up visits with primary
outpatient care services at the satellites. Patients were decen-
tralizedforARTfollow-upfromtheprimesitetothesatellites
if they met several criteria: (i) adults or older children on
first-line ART (or alternative first-line) for more than 6
months and stable; (ii) no evidence of active opportunistic
infectionordrugintolerance;(iii)ARTprovider’sconfidence
in patient adherence; at enrollment, all patients were given
generalHIV/ARTcounselingonone-on-onebasisandhadat
leasttwocontactswiththecounselorsbeforecommencement
of HAART; in addition, adherence was assessed at each
c l i n i cv i s i tu s i n gp a t i e n tr e c a l la n do u re l e c t r o n i cp h a r m a c y
database; and (iv) patient living closer to satellite than to
prime site.
The details of the various roles of health care staff at both
levels of care are shown in Table 1.
2.5. Statistical Analysis. Differences between groups were
compared using the Chi-square test for categorical vari-
ables and 𝑡-tests for continuous variables. We compared
immunovirologic outcomes between the prime and satellite
sites at 24 and 48 weeks. We also compared change in body
weight, hemoglobin levels, and time to HAART initiation
(defined as the period between enrollment for care and the
pick-up of the first ART prescription) between the sites.
C o xp r o p o r t i o n a lh a z a r dm o d e lw a su s e dt oe v a l u a t et h e
relationship between decentralization and the risk of death.
Inaddition,weassessedtheriskofvirologicfailure(VF)(viral
load>1000copies/mLasperprotocol)at12monthsoffollow-
up using a logistic regression model. The 48-week end point
viral load data was available for 648 patients (403 and 281 at
theprimeandsa tellitesites,resp .)andthesewerethen umber
of patients analyzed for the VF outcome. Adjustments in
multivariate analysis were made for sex, age, clinical stage at
initiation, baseline anemia, elevated creatinine, CD4 count,
program site, and educational status. Data analysis was per-
formedusingEpiInfoversion3.5.3(CDC,Atlanta,GA,USA)
a n dp l o t sc r e a t e du s i n gt h eM i c r o s o ftE x c e lg r a p hf e a t u r e .𝑃
values <0.05 were considered significant.
3. Results
The enrollment of patients by site and flow from recruitment
to inclusion in this study is shown in Figure 2.O v e r a l l ,
f e m a l e s( 5 3 8 1 )m a d eu p6 9 . 5 %o fa l lp a r t i c i p a n t sr e p o r t e di n
thisstudyand609(11.3%)werepregnantatthetimeofenroll-
ment. The mean age was 34±9 years with males enrolling for
care at older age compared to females (39 ± 9 versus 32 ± 8
years,𝑃 < 0.001).4712(60.8%)weremarriedand1394(17.8%)
reportedhavingnoformaleducation.ThemedianCD4count
at enrollment was 180cells/mm
3 (IQR: 4–1481) and males
e n r o l l e df o rc a r ea tal o w e rC D 4c o u n tc o m p a r e dt of e m a l e s
(152 versus 195cells/mm
3, 𝑃 < 0.001). A higher proportion
of males (65%) than females (51.2%) (𝑃 < 0.001)e n t e r edc a r e
with CD4 < 200cells/mm
3. There were 2195 (28.3%) patients
withadvancedWHOdiseaseandtheprevalentTBrateforthe
entire cohort was 10.1%. The details of baseline comparison4 AIDS Research and Treatment
Table 1: Profile and role of health workers at the prime and satellite sites in the decentralized ART program in Jos, Nigeria.
Category Prime site Satellite sites
Physicians
Specialist physicians running daily adult, pediatric, and
PMTCT services with daily mentoring of junior staff.
Concurrent activities include baseline assessment, ART
initiation, review of difficult cases, and switch to
second-line ART
General duty doctors providing integrated services 1-2
days a week. Weekly mentoring visits by the satellite
team with provision of technical assistance and
logistical support
Pharmacists Several pharmacists with dedicated adult and pediatric
tracks. Assisted by pharmacy assistants
One pharmacist for each performing combined adult
and pediatric dispensing on clinic days. Some are
assisted by pharmacy technicians/assistants
Nurses
Trained nurse/midwives with specialized training in
ART triage, reproductive health, and adult, pediatric,
and PMTCT services
Trained nurse/midwives providing integrated HIV
services at sites. Some sites have auxiliary nurses
Patient care
attendants
Trained adherence and medical health records
personnel dedicated to adult/pediatric/PMTCT clinics.
Nutrition counselors as well as clinical psychologists
providing general HIV/AIDS prevention education and
nutritional counseling
Nurses trained to provide general HIV/AIDS and
nutritional counseling
Expert patients
Trained expert PLWA provide adherence counseling,
vital sign measurement, anthropometry, and
defaulter/loss to follow up tracking
Available at some sites
Home-based care
volunteers/CBO
HBC volunteers provide peer support and promote
community care and services among PLWA.
CBOs not utilized
CBOs provide community-based OVC services
Total patients enrolled 
during period
14,437
7075
4880
3742
3729 4018
4019
4960
7362
Prime site Satellite sites
Initiating 
HAART
Included in 
analysis
Receiving
6months
HAART ≥
Figure 2: Flow chart of patients included in the study.
between patients at the satellite and prime sites are shown in
Table 2.
3.1.ComparisonofOutcomes. Forimmunologicoutcome,we
compared absolute CD4 count as well as median increase
from baseline over time points (Table 3 and Figure 3(a)). In
spite of presenting with significantly lower CD4 counts at
baseline, patients at the prime site had significantly higher
median increases at all subsequent follow-up visits and also
in median absolute counts except at the 48-week visit where
there was no difference between the sites in absolute CD4
count. The proportion of patients with undetectable VL
levels was higher at 12 and 48 weeks among patients at the
p r i m es i t e ,c o m p a r e dt ot h o s ea tt h es a t e l l i t e s( Figure 3(b)).
Virologic suppression rates were similar at 24 weeks between
the two groups.
Time in care refers to time since enrollment, which
encompasses both the pre-ART and ART periods, whereas
time on HAART refers only to the period spent on HAART.
These two end points differed significantly between the satel-
lites and prime site at the end of one year. Time to ART ini-
tiation was significantly longer at the satellite sites, compared
with the prime site (𝑃 < 0.001). There was no significant dif-
f e r e n c ei nt h ew e i g h ta n dh e m o g l o b i nl e v e l so ft h ep a t i e n t s
at the two sites at the end of the first year of treatment. The
detailsofclinicalandlaboratoryoutcomesandfollow-updata
are shown in Table 3.Th en u m be ro fd ea th sr e po rt edd i ff e r ed
significantlyoverthe12-monthfollow-upperiodbetweenthe
p r i m ea n ds a t e l l i t es i t e s .B a s e do no u rm o d e l ,p a t i e n t sc o u l d
be transferred from the tertiary site to the satellites and also
from the satellites to the tertiary site. One of the objectives
o ft h em o d e lw a st om o v et r e a t m e n ts e r v i c e sc l o s e rt ot h e
patients. Our rate of transfer captures patients who may have
moved from the tertiary to the satellite sites for the tertiary
site and from the satellites to the tertiary site for the satellite
sites.Thetransferratewassignificantlyhigherforthetertiary
site compared to the satellite sites.AIDS Research and Treatment 5
Table 2: Comparison of baseline characteristics between patients enrolled at the prime and satellite sites in the decentralized ART program
in Jos, Nigeria.
Characteristic Satellite (𝑛 = 3729)P r i m e ( 𝑛 = 4018) 𝑃 value
Proportion enrolled 48.1 51.9
Sex
Female 2700 (72.4) 2681 (66.7) <0.001
Male 1029 (27.6) 1337 (33.3)
Missing 0 (0.0) 0 (0.0)
Age, years
Median (IQR) 32 (15–80) 33 (15–81) 0.001
Missing 3 0
Marital status
Married 2390 (64.1) 2322 (57.8) <0.001
Single 531 (14.2) 898 (22.3)
Other 793 (21.3) 798 (19.8)
Missing 14 (0.4) 0 (0.0)
Educational attainment
No formal education 719 (19.3) 665 (16.5) 0.004
Primary 1148 (30.7) 862 (21.5)
Secondary 1107 (29.7) 1260 (31.4)
Tertiary 693 (18.6) 1221 (30.4)
Missing 62 (1.7) 10 (0.2)
Number unemployed 758 (21.3) 792 (19.9) 0.49
Missing 125 (3.3) 0 (0.0)
WHO staging
1 1718 (46.1) 1429 (35.6) <0.001
2 948 (25.4) 752 (18.7)
3 585 (15.7) 1257 (31.3)
4 179 (4.8) 174 (4.3)
Missing 299 (8.0) 406 (10.1)
Number with tuberculosis
∗ 324 (11.1) 70 (7.5) <0.001
Missing 254 (6.8) 953 (23.7)
High creatinine (>120𝜇mol/L) 205 (5.5) 276 (6.8)
Missing 17 (0.5) 48 (1.1)
Severe anaemia (Hb < 8g/dL) 209 (5.6) 155 (3.9) 0.0003
Missing 15 (0.4) 8 (0.1)
Median CD4 (cells/mm
3), IQR 184 (4–1481) 175 (5–1243) 0.0001
Missing 3 (0.0) 1 (0.0)
Advanced HIV disease
∗∗ 2008 (53.8) 2284 (56.8) <0.008
Median viral load (copies/mL) 37 357 43 456 0.04
Missing 389 (10.4) 12 (0.2)
Hepatitis B positive 454 (13.1) 776 (22.7) <0.001
Missing 227 (6.0) 605 (15.0)
Hepatitis C positive 308 (8.9) 522 (14.7) <0.001
Missing 281 (7.5) 455 (11.3)
Number of pregnant females 360 (13.5) 249 (9.8) <0.001
Missing 25 (0.6) 131 (3.2)
∗Both pulmonary and extrapulmonary; ∗∗CD4 < 200 cells/mm3.6 AIDS Research and Treatment
Table3:Outcomesthrough12monthsoffollow-upamongpatientsinitiatingantiretroviraltherapyinadecentralizedHIVtreatmentprogram
(2007–2011) in Jos, Nigeria.
Variable Satellite sites Prime site 𝑃 value
Time to HAART initiation (days) 84 32 <0.001
Time in care (months) 23 (6–98) 34 (6–98) <0.001
Duration on HAART (months) 17 (0.4–59) 23 (0.3–59) <0.001
Median CD4 increase (cells/mm
3)
12 weeks 53 128 <0.001
24 weeks 68 125 <0.001
48 weeks 91 123 0.03
Change in body weight (kg), mean (SD)
Baseline 57.1 (11.4) 58.6 (11.9) <0.001
12 weeks 57.0 (10.7) 59.1 (11.8) <0.001
24 weeks 57.1 (10.9) 58.5 (11.6) 0.003
48 weeks 57.5 (11.7) 58.2 (11.5) 0.11
Change in haemoglobin (g/dL)
12 weeks 11 11 0.001
24 weeks 11.5 11 0.68
48 weeks 11.8 12 0.39
Transfers (%) 205 (5.5) 349 (8.7) <0.001
Deaths (%) 201 (5.0) 85 (2.3) <0.001
Baseline
Satellites 184 237 252 275
Prime 175 303 300 298
100
150
200
250
300
350
P = 0.001
P = 0.11
12weeks 24weeks 48weeks
(a)
Satellites
Prime
36
43.1
45.3
46.9
48.8
53.3
0
10
20
30
40
50
60
P < 0.001
P = 0.21
P = 0.03
12weeks 24weeks 48weeks
(b)
Figure 3: (a) Line graph showing trend in median CD4 levels (cells/mm
3) at baseline through 48 weeks of follow-up between patients at
the prime and satellite sites in Jos, Nigeria. (b) Bar chart showing proportions of patients achieving undetectable viral load (<400copies/mL)
from 12 through 48 weeks of follow-up in patients at the prime and satellite sites in Jos, Nigeria.
When we adjusted for sociodemographic and biologic
variables, the factors associated with mortality in time-to-
event analysis were male sex, older age, enrollment at a satel-
lite site, low baseline hemoglobin, and CD4 < 50cells/mm
3.
Similarly, the factors predictive of virologic failure at 12
months were advanced WHO stage disease and CD4 count
>200cells/mm
3 (Table 4).
4. Discussion
Anestimated1.5ofNigeria’s3.5millionHIVpositivepersons
are in need of ART; however only a third of this number is
currently receiving these lifesaving medicines [1]. In order to
meet her treatment targets, there is need to explore different
models of decentralization of HIV services. Decentralization
of ART services is a key strategy for the expansion ofAIDS Research and Treatment 7
Table 4: Risk factors for death within 12 months and virologic failure in patients initiating ART in a decentralized HIV treatment program
(2007–2011) in Jos, Nigeria.
Variable Death Virologic failure
AHR 95% CI 𝑃 value AHR 95% CI 𝑃 value
Sex
Female 1 1
Male 1.60 1.06–2.42 0.02 0.88 0.66–1.18 0.40
Age (years)
<35 1 1
35–49 1.66 1.07–2.56 0.02 1.22 0.66–2.26 0.52
≥50 1.21 0.63–2.30 0.55 1.11 0.52–2.35 0.77
Baseline CD4 (cells/mm
3)
≥200 1 1.30 1.00–1.69 0.04
51–199 0.87 0.56–1.34 0.53 1.50 0.34–6.54 0.58
≤50 2.3 1.42–3.70 0.0006 5.13 1.93–13.65 0.001
Program level
Prime site 1 1
Satellite sites 5.05 3.31–7.70 <0.001 0.98 0.77–1.26 0.92
Haemoglobin (g/dL)
≥81 1
<8 2.86 1.30–6.29 0.008 1.16 0.67–2.01 0.57
WHO stage
1a n d2 1 1
3 and 4 0.99 0.66–1.49 0.98 1.50 1.22–2.06 0.0005
Creatinine (𝜇mol/L)
≤120 1 1
>120 1.09 0.59–2.01 0.77 1.05 0.63–1.76 0.83
Formal education
Any 1 1
None 0.85 0.51–1.43 0.57 0.85 0.60–1.20 0.36
treatment access to people living with HIV (PLHIV). Since
2007, our program utilized the hub-and-spoke model to
scale out ART from a congested tertiary-level hospital to 13
secondary-levelhealthfacilities.ScalingdownHIVtreatment
t ol o w e rl e v e l so fc a r ea p p e a r e dt ob eb o t hf e a s i b l ea n d
effective.However,inourstudy,pooreroutcomeswerefound
at lower level clinics compared to the primary hub hospital.
Therefore, further measures to optimize the provision of care
will be needed to fully sustain the long-term benefits of
decentralization.
We found the risk of death to be higher for patients
enrolledatthesatellitescomparedtotheprimesite.Thisfind-
ingagreeswithastudyinMalawi[18],whichreportedhigher
mortality among patients seen at health centers compared
to hospital setting. However, another study in Malawi [12]
reportedlowerdeathratesathealthcentersinadecentralized
ART program. Whereas the ART program in Malawi used
task shifting with downreferral of stable, less ill patients to
health centers from hospital setting, our hub-and-spoke
model entailed the secondary-level facilities enrolling new
patients irrespective of clinical status and encouraged the
referral of sick/unstable patients to the tertiary hospital after
an initial triage period. Our overall mortality for both levels
of care was lower compared to similar cohorts in SSA [19],
but the risk factors for death were similar to other cohorts
from the countries most affected by HIV; these are male
sex, anemia, and low baseline CD4 count [18, 20–22]. A
possible explanation for our lower rates may be our inability
to account for all deaths, as our database was not directly
linked to any public health records/registry and mortality
reporting was passive.
O n ek e ym e a s u r eo fH I Vt r e a t m e n ts u c c e s si st h ea b i l i t y
to sufficiently reconstitute the immune system to levels
where opportunistic infections (OIs) become less common
and cease to threaten survival in PLHIV. Achieving and
maintaining adequate level of CD4 counts is important
as many OIs are prevented when CD4 counts rise above
200cells/mm
3. Although our patients presented with very
lowbaselineCD4countsatbothlevelsofcare,thetwogroups
achieved impressive immunologic response to ART in the
firstyearwithpatientsattheprimesiteachievingsignificantly
higher increases. Studies reporting immunologic response to
ARTinAfrica[23–25] have obtained similar margins of CD4
increaseamongpatientsonART,withslightlylowerincreases
a m o n go l d e ra g eg r o u p s .Th eu s eo fp r o p h y l a c t i ca g e n t ss u c h
as cotrimoxazole among other initiatives will help to further8 AIDS Research and Treatment
improveimmunefunctionand sustain the benefits of ART as
programs scale out to rural areas with high burden of OIs.
Routine virologic monitoring, though uncommon in HIV
treatmentprogramsin resource-limitedsettings, remainsthe
gold standard for early detection of treatment failure.
Recent endorsement by WHO of virologic monitoring for
patients on HAART gives the best picture of treatment
response, and the ability to maximally suppress viral loads to
undetectable levels is a key outcome in ART programs. We
found more than half of our patients achieving undetectable
viral loads at one year of treatment. Studies [26–29]h a v e
reported varying rates of virologic response to treatment in
settingssimilartoourswithmajorityreportinghigherratesof
viralsuppressionthanweobservedinourstudy.Alargestudy
from South Africa, which compared treatment outcomes
between three levels of care, reported higher likelihood of
virologic suppression as well as other outcomes at primary
health centres, compared to regional and district level hospi-
tals [30]. Even though our study did not include any primary
health centre, one reason that may be responsible for the
poorer outcomes we reported at the satellites could be the
constraintoflimitedstaffingwhichwasarecurringissueatall
of our satellite sites. Although we did not assess medication
adherence in this study, poor or suboptimal adherence has
beenreportedtobelargelyresponsiblefortreatmentfailurein
ARTprogramsacrossSSA.Fortreatmentprogramstoensure
sustained adherence in the long term, medication adherence
support initiatives need to be an integral part of procedures
irrespective of the model of service delivery.
We used time to ART initiation as one of our outcome
measures in this study and found that patients at the satellite
sites had longer waiting time to commencement of ART
comparedtopatientsattheprimesite.Thismaybeexplained
b yt h ef a c tt h a tt h ep r i m es i t ew a sb e t t e rr e s o u r c e da n dc o u l d
decide ART eligibility at an earlier rate. Studies reporting
delays in ART initiation have cited various factors being
responsible for such delays [31–34]. Timely initiation of ART
in patients enrolling for care has implications for early mor-
tality, loss to follow-up, and other outcomes during subse-
quentfollow-ups.Delays ininitiationof ART couldbe dueto
health system, or patient-related factors, including pre-ART
attrition and system-mandated delays to allow for appro-
priate pretreatment counseling [35, 36]. These delays were
associated with excess rates of preventable morbidity and
mortality, especially in ART-eligible patients with advanced
HIV disease whoarealready atelevated riskofdeath. Theuse
of point-of-care testing and simplified guidelines, protocols,
andregimens,coupledwithefficient triagingofnewpatients,
will serve to minimize some of these unnecessary delays in
the context of decentralization.
The treatment model described here, a decentralized
program with treatment delivered through the hub-and-
spoke model, has allowed rapid scale-up, with an additional
7075 adult patients enrolled for care with 4880 initiating
ART in a 4-year period. The rapid increase of ART initiation
in the satellite sites is encouraging and suggests that the
availabilityofcareatthesecondarylevelreducesthecommon
barriers (travel time and cost) to ART uptake. Other aspects
of HIV care, such as pre-ART monitoring and long-term
adherence support, will be required to maintain delivery of
high quality care as we scale comprehensive HIV services
down to secondary and primary levels of care.
O n eo ft h es t r e n g t h so ft h i ss t u d yi st h a to u rd a t ao r i g -
inates from operational real-life program information col-
lected as part of routine monitoring and evaluation from a
public donor-supported HIV program in a high burden
country and may therefore reflect the challenges faced with
implementationof public sector programsin manyresource-
constrainedsettings.Secondly,wehaveanelectronicmedical
recordsystemthatincludesclinicallaboratoryandpharmacy
data, which improved access to longitudinal data for the
over 7000 patients included in this analysis. Thirdly, out-
comes such as CD4 counts and viral loads required optimal
adherence to the APIN ART monitoring protocol. One of
our concerns was regarding the accuracy and consistency
associatedwithuseofoperationaldata.Differentialcensoring
due to missing data between different levels of care could
not be completely discounted. Our mortality estimates may
be underestimates because we did not have access to any
public registries. However, our program has a tracking unit
that routinely generates a list of patients lost to follow-up
and this enabled us to document the exact disposition of
some patients who may have died outside of the health care
setting. Finally, our study is limited by the short follow-up
of 12 months and further studies will be required to evaluate
differencesinhealthcareprovisionandoutcomesbeyondthe
first year of ART, particularly retention and subsequent viral
suppression rates.
I nc o n c l u s i o n ,w eh a v es h o w nt h a tr a p i ds c a l e - u po fA R T
delivery through a decentralized secondary-level care pro-
gram is feasible in our resource-limited setting and produces
outcomescomparabletothosereportedinotherSSAsettings.
The high rates of detectable viral load in patients on ART at
our satellite sites highlight the challenges of program imple-
mentation at less well-resourced health centers and efforts
have been made to intensify support for medication adher-
ence and to maintain quality of care by health systems
strengtheningaswescaleouttosecondaryandprimaryfacil-
ities.
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